2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)2109 - North Ryde - Macquarie University Hospital (WITHDRAWN)2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (WITHDRAWN)2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (WITHDRAWN)2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (WITHDRAWN)

3000 - Melbourne - Peter MacCallum Cancer Centre (WITHDRAWN)3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (WITHDRAWN)

4215 - Southport - Tasman Oncology (WITHDRAWN)4655 - Urraween - Cancer Care Service, Hervey Bay Hospital (WITHDRAWN)4670 - Bundaberg - Bundaberg Hospital, Genesis Cancer Care (WITHDRAWN)

NCT05720130

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study). (TheraPb-ADVC001)

NCT05613023

PACE-NODES. A Phase III Randomised Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT

NCT05521412

EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T: Phase I/II Study (VIOLET)

NCT05519449

A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (PSMA-007-001)

NCT05413421

An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer (ORIC-944-01)

NCT05393791

ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer

NCT05367440

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

NCT04925648

PICAASO / CA180-722: Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction (PICASSO)

NCT04876651

A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug (177Lu-TLX591-002)

NCT04868604

A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

NCT04769817

Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) Prospective Patient Registry of Men Treated With PSMA Theranostics (PMC-20-164)

NCT04606446

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS (KAT6)

NSW2050 - Camperdown - Chris O'Brien Lifehouse (TERMINATED)

NCT04597411

AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy (PSMA-617-100)

NCT04585750

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

NCT04221542

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

NCT03522064

High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer (HiTeCH)

NCT03386045

NA

Optimal Prostate Fractionation Study

NCT03073278

NA

Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate (Focal-SBRT-prostate)

NCT02960022

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study (9785-CL-0123)

2076 - Wahroonga - Sydney Adventist Hospital (COMPLETED)2485 - Tweed Heads - The Tweed Hospital (COMPLETED)2640 - Albury - Border Medical Oncology Research Unit (COMPLETED)

3000 - Melbourne - Peter MacCallum Cancer Centre (COMPLETED)3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)3165 - East Bentleigh - Peter MacCallum Cancer Centre Moorabbin Campus (COMPLETED)

QLD4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (COMPLETED)

NCT02861573

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

ACTRN12625000971437

Dose Optimisation and PSMA Receptor intensification with 177Lu-PSMA Therapy in Patients Diagnosed with Metastatic Castrate Resistant Prostate Cancer : A Randomised Phase II trial: OPTIMAL-PSMA

ACTRN12625000487415

Not Applicable

Efficacy of toxicity reduction with urethra sparing stereotactic ablative body radiation therapy for prostate cancer, assessing toxicities and quality of life in patients with intermediate risk prostate cancer. (TRUST)

ACTRN12625000259448

Not Applicable

Stereotactic ablative body radiation therapy with nodal irradiation of prostate cancer, assessing toxicities and quality of life in patients with high risk and/or node positive prostate cancer. (SNIPER)

ACTRN12625000224426

Not Applicable

Salvage sTereotactic Ablative radiotherapy for patients with Recurrent prostate cancer With Androgen suppression and Rectal Spacer, assessing toxicity and quality of life (STARWARS)

ACTRN12625000198426

Not Applicable

2-fraction Stereotactic ultra-HypOfractionated radiation Therapy of the proState, assessing toxicities and quality of life in patients with intermediate risk prostate cancer (2SHOTS)

ACTRN12624001458527

Randomised Phase 2 study of sphingosine kinase inhibitor (opaganib) in addition to darolutamide in people with poor prognostic metastatic castration resistant prostate cancer (mCRPC) based on a companion circulating lipid biomarker, PCPro (ANZUP2205) (DARO-LIPID)

ACTRN12624001123538

A Multicentre, Open-label, Interventional, Repeated Dose Escalation/De-escalation Phase I Trial to Determine the Optimal Biological Dose, and Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of Actinium (225Ac) Ibu-DAB-PSMA for the Treatment of PSMA-positive Progressive Metastatic Castration Resistant Prostate Cancer (ITM-2221-01CT)

ACTRN12624001119583

Not Applicable

Transperineal prostate biopsy under local anaesthetic in adults with suspected or confirmed prostate cancer: an analysis of cost, efficacy and patient tolerability in Australia

ACTRN12624000644561

Not Applicable

A randomised controlled trial comparing animation-based with written patient information for educating patients about robotic-assisted radical prostatectomy

ACTRN12624000582550

Evaluating the efficacy of bipolar androgen therapy in extending metastasis-free survival in patients with M0 castrate-resistant prostate cancer with prostate specific antigen progression but not radiological or clinical progression on darolutamide (WOMBAT) - ANZUP 2201

ACTRN12624000110583

Not Applicable

SOCRATES PILOT: Standard of Care Randomised Treatment Evaluation Studies (SOCRATES-PILOT)

ACTRN12623001072606

A phase 1a/b dose-escalation and dose-expansion study to evaluate Lutetium-177-PSMA I&T (Lu-PSMA) with radiosensitising Capecitabine in patients with metastatic castration-resistant prostate cancer (mCRPC) (LuCape)

ACTRN12623000919617

A clinical trial exploring MR guided adaptive stereotactic radiotherapy boost to the prostate combined with stereotactic radiotherapy to the whole pelvis (MR-PROTEUS)

ACTRN12623000902695

Not Applicable

MRI Guided Stereotactic Focal Ablation of Prostate Cancer investigating feasibility, Toxicity and Patient Reported Outcomes. (MR-Ablate)

ACTRN12623000216617

A pilot, feasibility study of 177Lu-DOTA-Rosopatamab (TLX591) therapy in castrate resistant prostate adenocarcinoma patients showing progression on radioligand therapy using PSMA small molecule ligands (RESCUE)

ACTRN12623000160639

A Randomized, Open-Label, Phase 2 Study of Darolutamide as Single Agent or in Combination with EPI-7386 as a Neoadjuvant Treatment for Patients Undergoing Prostatectomy for Localized Prostate Cancer (DaSCENT)

ACTRN12623000073606

A Single-Arm, Open-Label, Prospective, Phase 0 Trial Evaluating the Safety and Efficacy of Salvage 177Lu-PSMA-I&T in Prostate Specific Antigen (PSA) Biochemical Failure After Radical Prostatectomy for High-Risk Prostate Cancer (SLAP-trial)

ACTRN12622001478707

Not Applicable

A multi-centre, randomised phase 2 clinical trial of early salvage radiotherapy versus surveillance on the incidence of biochemical recurrence after radical prostatectomy for men with prostate cancer, incorporating clinical and imaging-based risk stratification. (DIPPER)

ACTRN12622001378718

Phase I/IIa Dose Escalation and Toxicity Study of [212Pb]Pb-ADVC001 in Metastatic Prostate Adenocarcinoma (TheraPb – Phase I/II) (TheraPb-phase-I-II)

ACTRN12622001003763

A multi-centre, open label phase 2 trial investigating the effect of evolocumab in addition to chemotherapy or androgen receptor signalling inhibitor therapy on the circulating lipid profile of men with metastatic castration-resistant prostate cancer (X22-0072)

ACTRN12621000611820

Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction (PICAASO)

ACTRN12621000227897

Not Applicable

Feasibility of Magnetic Resonance Imaging guided stereotactic reirradiation in patients who have previously received radiation for prostate cancer and have biochemical and local recurrence of cancer within the prostate (PRIUS-MR)

ACTRN12618001667202

A Randomised Trial of External Beam Radiation Therapy (EBRT) Alone versus EBRT in Combination with 177Lu-PSMA Theranostic in Patients with Biochemically Recurrent Prostate Cancer (to determine the proportion of participants in each group with a 50% decline in PSA through to the end of the trial) - a phase 3 study (TARGET)

ACTRN12616001021460

A Phase I trial of Sodium Valproate/MetformIn Combination as neoadjuvant therapy for ProstatE canceR (VIPER-1-trial)

NCT06909825

A Phase 2, Open-label, Multi-centre Study of FPI-2265 (225Ac-PSMA-I&T) and Olaparib in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) (FPI-2265-203)

NCT05396833

An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the ATR Inhibitor Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Patients With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 320) (2022-500287-35-00--MS201924-0020)

NCT04122976

Darolutamide Observational Study in Non-metastatic Castration-resistant Prostate Cancer Patients (DAROL)

NCT02643511

Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer (STGAF)

ACTRN12621000747820

TaxAdapt: Feasibility, acceptability and safety of adaptive dosing of docetaxel in men with metastatic castrate-resistant prostate cancer

androgen axis	40%
AR	35%
CYP17A1	22%
PSMA	21%
PARP	10%
oestrogen axis	8%
PD-1/PD-L1	5%
PARP1-selective	5%
STEAP1	4%
PD-1	4%
B7H3	3%
CYP11A1	3%
ER	3%
KLK2	2%
KAT6	2%
EZH2	2%
LHRH	2%
Nectin4	2%
ATR	2%
CDK4	2%
CDK4 selective	2%
BCR-ABL1	2%
KIT	2%
PDGFRA	2%
SRC	2%
YES1	2%
GnRH	2%
VEGF	2%
hGIIA-vimentin	1%
PSMA∕STEAP1	1%
STEAP2	1%
CDK2	1%
ERBB2	1%
ERBB3	1%
PRC2 complex	1%
CDK6	1%
TP53	1%
TP53 Y220C	1%
HIF2a	1%
TIGIT	1%
sphingosine kinase-2	1%
HMG-CoA reductase	1%
antiandrogen,AR NTD	1%
PCSK9	1%
HDAC	1%
ATM	1%
PD-L1	1%

ARTICANZ - Beta (ver 0.91)

Search results

Prostate and Urogenital / Prostate - Advanced/metastatic

Filters